

Cartherics and panCELLa announce collaborative agreement for cell therapy

15 February 2019 | News

panCELLa will integrate their FailSafe™ technology into Cartherics' proprietary homozygous HLA haplotype cells



Cartherics and panCELLa have announced their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.

Prof. Alan Trounson, CEO Cartherics said, "This technology is an important step to ensure the safety of the next generation of very effective gene-edited stem cell-derived immunotherapies."

Dr. Andras Nagy, President and CSO of panCELLa said, "We anticipate that this partnership will provide for the highest level of cell therapy safety, stated. "We are pleased to partner with Cartherics to address the needs of immunotherapy treated cancer patients and to generate FailSafe™ cells for cell therapies in regenerative medicine. It is our mission to provide off-the-shelf universally safe cell therapies for all humankind."

panCELLa will integrate their FailSafe™ technology into Cartherics' proprietary homozygous HLA haplotype cells to bring the power of safe cell therapy to a greater number of patients.